Evaluating online nutrition information: a scoping review of young adults’ source preferences and criteria for credibility and trustworthiness - Report - MDSpire
Advertisement
Evaluating online nutrition information: a scoping review of young adults’ source preferences and criteria for credibility and trustworthiness
Clinical Report: Assessing Digital Nutrition Resources for Young Adults
Overview
This scoping review identifies 82 factors influencing the trustworthiness and credibility of digital nutrition information from the perspective of young adults, based on a review of 48 papers.
Background
The internet has become a primary source of health information for young adults, with many actively seeking nutrition-related content online. This review examines how various factors, including ethnicity and education, influence perceptions of digital nutrition resources.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
48 papers were included in the review, identifying 82 factors related to trust and credibility.
The most frequently reported factors were clarity of information (n = 14), prior background knowledge (n = 13), and receiver's education (n = 7).
Only 25% of the papers included a multi-ethnic sample, indicating a lack of diversity in research.
46 additional factors not covered by existing frameworks were identified.
75% of the papers did not report the ethnicity of study participants.
Clinical Implications
Healthcare professionals should be aware of the factors influencing young adults' perceptions of digital nutrition information.
Conclusion
Further research is needed into the factors affecting trust in digital nutrition resources.
Although most large US-based medical societies in a cross-sectional study explicitly suggested considering economic or resource use–related evidence during guideline development, only 3.8% of individual recommendations included that information in the recommendation statement itself.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
